In this study, the Ganweikang tablet increased the expression of PPARα, suggesting that the Ganweikang tablet may increase the hepatic FAO and thereby attenuating NAFL and NASH. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.